Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.
Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...
MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback